This topic has 2 replies, 2 voices, and was last updated 10 months ago by 
.
-
Posts
-
-
In this episode of the Morale Monologue, I’m discussing another biopharmaceutical company by the name of Scholar Rock, and their potential treatment known as SRK-015. I discuss how SRK-015 impacts our body, and how it differs from Spinraza, Zolgensma and risdiplam. While it may be over a year before this potential treatment gets approved by the FDA, it’s still proof that pharmaceutical companies are making advancements toward new treatments for those of us who suffer from spinal muscular atrophy.
- SRK-015 Data Continue to Support Potential for SMA, Scholar Rock Says: https://smanewstoday.com/2020/02/21/srk-015-data-continue-to-support-potential-for-sma-scholar-rock-says/
- Early Data Support SRK-015 Development for SMA Types 2–3, Scholar Rock Says: https://smanewstoday.com/2019/10/09/early-data-support-srk-015-development-for-sma-types-2-3-scholar-rock-says/
- Scholar Rock Announces Additional Preclinical Data Supporting SRK-015 as Potential SMA Treatment: https://smanewstoday.com/2018/11/30/additional-preclinical-data-supports-srk-015-as-potential-sma-treatment/
-
-
-
Viewing 2 reply threads
- You must be logged in to reply to this topic.
